Chanelle Stidham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chanelle Stidham has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Heyrend
Intermountain Primary Children's Hospital Salt Lake City Utah USA
1 shared publication - Gitte Y. Larsen
Division of Pediatric Critical Care, Department of Pediatrics, Primary Children’s Hospital, University of Utah, Salt Lake City, USA
1 shared publication - Jared Olson
Division of Pediatric Infectious Diseases, Department of Pediatrics, Spencer Fox School of Medicine, University of Utah , Salt Lake City, UT
1 shared publication - Jennifer K. Workman
Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT
1 shared publication - Lauren Burgunder
Division of Pediatric Critical Care, Department of Pediatrics, Primary Children’s Hospital, University of Utah, Salt Lake City, USA
1 shared publication - Roni D. Lane
Division of Pediatric Emergency Medicine, Department of Pediatrics, Primary Children’s Hospital, University of Utah, Salt Lake City
1 shared publication
Latest Publications
- 21 March 2022
- Published by Springer Nature in Pediatric Drugs
- Vol. 24 (3) , 193-205
Medication and Fluid Management of Pediatric Sepsis and Septic Shock
Sepsis is a life-threatening response to infection that contributes significantly to neonatal and pediatric morbidity and mortality worldwide. The key tenets of care include early recognition of potential sepsis, rapid intervention with appropriate fluids to restore adequate tissue perfusion, and empiric antibiotics to cover likely pathogens. Vasoactive/inotropic agents are recommended if tissue perfusion and hemodynamics are inadequate following initial fluid resuscitation. Several adjunctive therapies have been suggested with theoretical benefit, though definitive recommendations are not yet supported by research reports. This review focuses on the recommendations for medication and fluid management of pediatric sepsis and septic shock, highlighting issues related to antibiotic choices and antimicrobial stewardship, selection of intravenous fluids for resuscitation, and selection and use of vasoactive/inotropic medications. Controversy remains regarding resuscitation fluid volume and type, antibiotic choices depending upon infectious risks in the patient’s community, and adjunctive therapies such as vitamin C, corticosteroids, intravenous immunoglobulin, and methylene blue. We include best practice recommendations based on international guidelines, a review of primary literature, and a discussion of ongoing clinical trials and the nuances of therapeutic choices.
- 21 March 2022
- Published by Springer Nature in Pediatric Drugs
- Vol. 24 (3) , 193-205
Medication and Fluid Management of Pediatric Sepsis and Septic Shock
Sepsis is a life-threatening response to infection that contributes significantly to neonatal and pediatric morbidity and mortality worldwide. The key tenets of care include early recognition of potential sepsis, rapid intervention with appropriate fluids to restore adequate tissue perfusion, and empiric antibiotics to cover likely pathogens. Vasoactive/inotropic agents are recommended if tissue perfusion and hemodynamics are inadequate following initial fluid resuscitation. Several adjunctive therapies have been suggested with theoretical benefit, though definitive recommendations are not yet supported by research reports. This review focuses on the recommendations for medication and fluid management of pediatric sepsis and septic shock, highlighting issues related to antibiotic choices and antimicrobial stewardship, selection of intravenous fluids for resuscitation, and selection and use of vasoactive/inotropic medications. Controversy remains regarding resuscitation fluid volume and type, antibiotic choices depending upon infectious risks in the patient’s community, and adjunctive therapies such as vitamin C, corticosteroids, intravenous immunoglobulin, and methylene blue. We include best practice recommendations based on international guidelines, a review of primary literature, and a discussion of ongoing clinical trials and the nuances of therapeutic choices.